Beyond lifestyle modifications and the management of blood pressure and lipid levels, the early administration of SGLT-2 inhibitors in patients with type 2 diabetes who are at high cardiovascular risk is recommended to prevent the onset of HF. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.